Combining PRP With Shockwave for Tendinopathy Protocols

Clinical protocols for combining PRP with shockwave for tendinopathy sequence shockwave therapy either as a preparatory step to induce microvascular ingrowth prior to biologic delivery, or as a secondary intervention four to six weeks post-injection to stimulate tenocyte proliferation without disrupting the autologous fibrin clot. By pairing focused or radial acoustic energy with autologous biologics, clinical teams address both the degenerative hypovascular matrix and cellular signaling deficits of chronic recalcitrant tendons. Mastering specific energy thresholds, biological preparation timing, and device staging ensures practices protect tissue viability while optimizing functional recovery pathways.

The Biological Rationale for Dual-Modality Tendon Care

Chronic tendinopathy is characterized by failed healing, disorganized collagen (predominantly Type III rather than Type I), neovascularization with accompanying nerve ingrowth, and a deficit in functional tenocyte activity. Single-modality interventions sometimes plateau when addressing both the mechanical microenvironment and the cellular signaling deficit simultaneously.

When evaluating biologics alongside energy-based devices, the physiological rationale centers on complementary mechanisms of action:

• Extracorporeal Shockwave Therapy (ECSWT): Delivers acoustic pressure waves that create controlled micro-cavitation and shear stress within the tendon matrix. Through mechanotransduction, this physical stimulus encourages local neovascularization, modulates pain fibers (via Substance P depletion and gate-control mechanisms), and upregulates endogenous growth factor expression.
• Platelet-Rich Plasma (PRP): Delivers a supraphysiological concentration of autologous platelets directly to the lesion site under image guidance. Upon activation by exposed tendon collagen, alpha granules release platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF), creating a localized chemotactic and mitogenic environment for tenocytes.

By combining the two, the clinician utilizes ECSWT to alter the physical stiffness and vascularity of the extracellular matrix while relying on PRP to supply the concentrated biochemical payload necessary for cellular recruitment and matrix synthesis.

Sequencing Strategies: Pre-Conditioning vs. Post-Injection Remodeling

A primary clinical question for orthopedic and sports medicine doctors is how to time the energy delivery relative to the injection. Applying high-energy focused shockwave immediately after a PRP injection is frequently avoided by practitioners out of concern that intense acoustic cavitation could disperse the localized fluid bolus or prematurely disrupt the forming fibrin scaffold.

Instead, practices generally adopt one of three structured clinical sequencing frameworks based on lesion chronicity, calcific deposits, and patient scheduling constraints.

1. The Pre-Conditioning Protocol (ECSWT Followed by PRP)

In long-standing, fibrotic, or calcific tendinopathies (such as chronic calcific supraspinatus tendinopathy or recalcitrant plantar fasciopathy), the tissue bed is often densely avascular.

• Phase 1 (Weeks 1–3): A series of weekly radial or focused ECSWT sessions is administered to disrupt calcific deposits, increase local microvascular perfusion, and initiate cellular mechanotransduction.
• Phase 2 (Week 4): Once the local tissue environment is vascularly primed, an ultrasound-guided leukocyte-poor or leukocyte-rich PRP injection (selected based on the specific tendon pathology and clinician preference) is performed.
• Phase 3 (Weeks 5+): Progressive eccentric loading and physical rehabilitation begin once acute post-injection soreness subsides.

2. The Delayed Remodeling Protocol (PRP Followed by ECSWT)

When the primary pathology involves a partial-thickness intrasubstance tear alongside tendinosis (common in the patellar, Achilles, or common extensor tendon), clinicians often prioritize structural and biochemical scaffolding first.

• Phase 1 (Day 0): Ultrasound-guided PRP injection into the hypoechoic defect, often accompanied by needle tenotomy (fenestration) to induce bleeding and mechanically break up scar tissue.
• Phase 2 (Weeks 0–2): Relative rest, avoidance of NSAIDs, and basic range-of-motion protection while the initial inflammatory and proliferative phases progress undisturbed.
• Phase 3 (Weeks 3–6): Introduction of weekly ECSWT sessions. At this stage, the initial fibrin clot has transitioned into early granulation tissue; mechanical stimulation via shockwave helps guide collagen fiber alignment along lines of stress and addresses persistent peritendinous pain.

3. Same-Day Sequential Application (ECSWT Immediately Prior to PRP)

For practices serving traveling patients or those requiring consolidated care, same-day sequencing is occasionally utilized, provided the order of operations is strictly maintained.

• Step 1: ECSWT is applied to the target tendon and associated myofascial kinetic chain first.
• Step 2: The skin is prepped, the patient's blood is drawn and processed, and the PRP injection is administered immediately afterward into the pre-stimulated tissue bed.
• Clinical Note: Because ECSWT can induce transient local hyperemia and temporary analgesic effects, clinicians rely strictly on anatomical landmarks and ultrasound imaging rather than patient pain feedback during the subsequent injection.

Clinical Protocol Checklist for Combined Therapy

When standardizing a combined tendinopathy protocol across clinical providers in a practice, the following clinical parameters should be defined in the chart documentation:

• Diagnostic Baseline: Confirm tendinosis vs. macro-tearing via musculoskeletal ultrasound or MRI; document baseline functional pain scores.
• Medication Washout: Verify discontinuation of non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids prior to and following the PRP phase to prevent inhibition of platelet cyclooxygenase pathways.
• PRP Formulation Selection: Specify centrifugation parameters, target platelet concentration, and leukocyte inclusion (e.g., leukocyte-rich PRP is frequently discussed in clinical literature for chronic tendinopathies to provoke a controlled inflammatory healing cascade, whereas leukocyte-poor formulations are standard for intra-articular spaces).
• Shockwave Modality and Dosing: Distinguish between focused shockwave (deep penetration, precise focal zone for insertional tendinopathies or bone-tendon junctions) and radial pressure wave (superficial, broader propagation for mid-substance tendinopathies and myofascial chains). Record energy flux density (mJ/mm²), frequency (Hz), and total pulses.
• Rehabilitation Integration: Coordinate timing with physical therapy so eccentric and heavy slow resistance (HSR) loading protocols do not conflict with the acute post-PRP inflammatory window.

Operational Considerations for Practice Managers

While the physician focuses on tissue pathology and energy dosing, integrating a combined PRP and ECSWT service line requires deliberate operational structuring by the practice manager. Combining a capital equipment modality with a consumable biologic impacts room turnover, staffing delegation, and fee-for-service packaging.

Workflow and Staffing Delegation

A standalone PRP procedure requires phlebotomy, centrifugation time (typically 10 to 20 minutes depending on the system), sterile tray setup, and physician time for ultrasound-guided delivery. ECSWT sessions, depending on state scope-of-practice regulations, can often be delegated to trained mid-level providers, physical therapists, or medical assistants under physician supervision.

If utilizing a same-day pre-conditioning workflow, the operational sequence is highly efficient: the clinical assistant draws the blood, starts the centrifuge, and administers the shockwave session while the biologic spins. By the time the ECSWT session concludes, the PRP is prepared, and the physician enters the room solely for the ultrasound-guided injection. This eliminates dead room time during centrifugation.

Procurement, Cost Per Treatment, and Bundling

From a financial standpoint, the two modalities have very different cost structures:

• ECSWT represents a fixed capital asset cost with minimal per-treatment consumable expenses (primarily acoustic coupling gel and periodic handpiece transmitter maintenance).
• PRP carries a variable consumable cost per procedure (specialized concentration kits, anticoagulants, phlebotomy supplies, sterile ultrasound probe covers, and needles).

Because both regenerative modalities are predominantly cash-pay in the United States, bundling a multi-session ECSWT package with a single PRP injection allows practices to increase the overall value of the treatment plan while blending the high gross margin of shockwave therapy with the consumable overhead of the biologic kit.

What This Means for Your Practice

For practices already offering either orthobiologics or extracorporeal shockwave therapy, formalizing a combined tendinopathy pathway is one of the most logical clinical expansions available:

1. Audit Current Patient Volume: Identify chronic tendinopathy cases (lateral epicondylitis, plantar fasciitis, Achilles, patellar, and rotator cuff tendinopathies) that have responded only partially to monotherapy or physical therapy.
2. Standardize Sequencing Pathways: Have clinical leadership establish written guidelines dictating when to use pre-conditioning vs. post-injection ECSWT based on ultrasound findings.
3. Structure Transparent Care Packages: Work with billing and front-desk coordinators to create clear, bundled self-pay packages that cover the biologic injection, the designated series of shockwave sessions, and follow-up evaluations.
4. Align Equipment and Consumables: Ensure your centrifugation systems produce consistent, reproducible platelet concentrations and that your acoustic wave hardware matches the depth requirements of the orthopedic pathologies you treat.

If your clinic is evaluating the addition of focused or radial shockwave systems, or looking to streamline procurement for consistent autologous biologic preparation kits, contact our team to schedule a clinical and operational consultation.